These are inhibitors of the hepatitis C virus (HCV) NS3/4A protease and have been approved for the treatment of Hepatitis C. In spite of the fact that NS3/4A is a serine protease, whereas the Mpro has an active cysteine residue, and in spite of clear differences in amino-acid sequence and three-dimensional structure, we tested whether these compounds are inhibitors of the SARS-CoV-2 Mpro. This evidence concerns the gene KRAS and hepatitis C virus infection.